China-based Lexenpharm has formed a partnership with compatriot firm Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) to develop LXP2311 and LXP0531, long-acting drugs targeting asthma and chronic obstructive pulmonary disease (COPD) for the mainland Chinese market.
Partnership Focus
The collaboration leverages Lexenpharm’s technical capabilities in respiratory diseases and Sun-Novo’s clinical development strengths. Financial details of the partnership were not disclosed.
Company Background
Founded in 2015 in BioBAY, Suzhou, Lexenpharm focuses on the R & D of innovative drugs for the respiratory, ocular, and central nervous systems. The company holds marketing approvals for five inhalation formulation products in China and three in the US. It boasts Asia’s largest sterile formulation production base and organ-targeted delivery technology platform based on “blowing, filling, and sealing” technology.-Fineline Info & Tech
Leave a Reply